Parkinson's disease treatment: the current and future landscape

​​Explore Parkinson's disease and access the tools you need to better understand this complex condition.     

​

​Overview

​​​​>> In collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF), we developed a range of RabMAb® products to bring you the tools you need for Parkinson’s disease research. Please see here to find out more about these products and our partnership.

​​

Parkinson's disease pathway

Explore our interactive Parkinson's disease pathway poster to understand the interactions between proteins in this complex disease. Find the best products for your target of interest by reading the pop ups and product tables that include Abcam's full product offering.

Get the pathway poster

​

Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge

Professor Barker explains where we are with research in 2019 and how our understanding of the disease has progressed, before exploring emerging trends and therapies.

Emerging trends discussed include the role of alpha-synuclein, drug repurposing, providing ‘fertilizer’ to dopamine cells such as in GDNF trials, stem cell-derived dopamine replacement, and gene therapy.

​​

​15:55 minutes - Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge.


Cerebrovasular pathology in Parkinson's disease

Learn how cerebrovascular lesions may contribute to changing connectivity within the brain and result in more severe PD from Professor Angelo Antonini, Professor of Neurology at the Department of Neurosciences, University of Padova.

Here Prof. Antonini explains how people with vascular lesions in the brain differ in clinical manifestations and response to traditional PD medications from those without lesions. He also talks us through imaging tracers available for studying cerebrovascular pathology.  

3:40 minutes - Professor Angelo Antonini, Professor of Neurology, Department of Neurosciences, University of Padova.

​​

​​​​​​


​